Straits Times Index
3,304.99 +15.57 (+0.47%) S&P 500
5,308.15 +61.47 (+1.17%) Dow
39,908.00 +349.89 (+0.88%) Nasdaq
16,742.39 +231.21 (+1.40%) Bitcoin USD
66,299.09 +4,051.47 (+6.51%) CMC Crypto 200
1,375.85 -18.20 (-1.31%)
REGN May 2024 770.000 put
- Zacks
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.
- GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell Current treatment options for adolescents with CRSwNP leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps TARRYTOWN, N.Y. and PARIS, May 13, 2024 (GLOBE NEWSWIRE) -
- Simply Wall St.
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past week
Key Insights Institutions' substantial holdings in Regeneron Pharmaceuticals implies that they have significant...
